Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 8/20 | 0.51 |
| ▸ | LYN | P07948 | 8/20 | 0.51 |
| ▸ | SRC | P12931 | 8/20 | 0.51 |
| ▸ | KDR | P35968 | 8/20 | 0.51 |
| ▸ | INSR | P06213 | 7/20 | 0.51 |
| ▸ | HCK | P08631 | 4/20 | 0.51 |
| ▸ | BRAF | P15056 | 5/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9967474 | 0.91 | LCK (0.49) | LCKLYNSRCKDRINSR | |
| SCHEMBL3584308 | 0.89 | BRAF (0.45) | LCKLYNSRCKDRINSR | |
| SCHEMBL3577332 | 0.89 | LCK (0.56) | LCKLYNSRCKDRINSR | |
| SCHEMBL3594891 | 0.89 | LCK (0.47) | LCKLYNSRCKDRINSR | |
| SCHEMBL9967414 | 0.89 | LCK (0.56) | LCKLYNSRCKDRINSR | |
| SCHEMBL9967475 | 0.89 | LCK (0.48) | LCKLYNSRCKDRINSR | |
| SCHEMBL9967420 | 0.89 | LCK (0.51) | LCKLYNSRCKDRINSR | |
| SCHEMBL9967419 | 0.89 | LCK (0.65) | LCKLYNSRCKDRINSR | |
| SCHEMBL9967421 | 0.89 | LCK (0.52) | LCKLYNSRCKDRINSR | |
| SCHEMBL9967413 | 0.88 | LCK (0.56) | LCKLYNSRCKDRINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202876-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-06-19 | — | — | US | disclosed |
| US-8202876-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-06-19 | — | — | US | disclosed |
| US-20100029605-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-02-04 | — | — | US | disclosed |
| US-20100029605-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029605-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | FYN, ABL2, LCK | LCK 3/4885LYN 12/4885SRC 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.